# 24th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents

> **NIH NIH R13** · UNIVERSITY OF COLORADO DENVER · 2022 · $15,000

## Abstract

ABSTRACT
This conference grant application requests funds to help support the 24th International Conference on Kaposi's
Sarcoma Herpesvirus and Related Agents in 2022. This annual conference, held since 1994, brings together
researchers and clinicians working on the oncogenic human herpesvirus, Kaposi's sarcoma herpesvirus
(KSHV), and other closely related pathogens. KSHV is the etiological agent of Kaposi's sarcoma (KS), which is
still one of the most prevalent cancers in Africa, especially in HIV-1 infected individuals. Requested funds will
be used to reduce the conference registration costs for outstanding pre- and post-doctoral trainees, historically
under-represented minorities, and scientists from lower income countries, especially those from Africa who
study oncogenic DNA viruses and the cancers associating with these viruses. The goals of these meetings are
consistent with the mission statements of the NIH, NCI, NIAID, and NIDCR, namely, to advance and promote
the pace of research on infections associated with human cancer and other diseases, including in the setting of
HIV-AIDS. The KSHV conference will be held in Denver, Colorado, USA, from the afternoon of June 26th
through June 29th, 2022. This meeting will further be organized to enable both in-person attendance as well as
virtual participation from researchers across the globe who are not able to attend in-person. Costs for the
conference will be raised from registration fees paid by the conferees and contributions from host institutions,
foundations, and pharmaceutical and biotechnology companies. The major focus of the KSHV meeting is the
biology of oncogenic herpesviruses and associated human diseases, with specific emphasis on viral
pathogenesis, viral latency and reactivation, viral gene expression and replication, host responses to infection,
epidemiology, vaccine development, therapeutic intervention, clinical and translational research. In addition to
KSHV, studies related to relevant animal models, including herpesvirus saimiri (HVS), murine
gammaherpesvirus-68 (MHV-68), and rhesus rhadinovirus (RRV) will be presented. The 24th International
Conference on Kaposi's Sarcoma-Associated Herpesvirus and Related Agents will continue the tradition of this
dynamic, annual scientific conference, to bring together a diverse audience of researchers and clinicians to
facilitate the conduct of both translational and basic research on KSHV and KS, to foster new collaborations,
and to explore novel therapeutic strategies for treating patients with ailments associated with KSHV in diverse
populations and geographies, particularly in the context of HIV-AIDS.

## Key facts

- **NIH application ID:** 10484863
- **Project number:** 1R13CA271925-01
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** Linda F. Van Dyk
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $15,000
- **Award type:** 1
- **Project period:** 2022-06-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10484863

## Citation

> US National Institutes of Health, RePORTER application 10484863, 24th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents (1R13CA271925-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10484863. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*